Children's Hospital and Research Center Oakland
Oakland, California, 94609, United States
NCT Number: NCT00508027
Recent clinical and experimental data indicate that statins have effects beyond cholesterol lowering that may be beneficial in sickle cell disease by protecting the vascular endothelium. Statins have been shown to attenuate endothelial dysfunction through their anti-inflammatory, anti-oxidant and anti-thrombotic properties. This phase I/II dose-escalating trial is designed to assess the safety and potential clinical efficacy of oral simvastatin (Zocor)in adolescents and adults with sickle cell disease (SCD).
Looking for future studies?
Notify Me13 year and older
All sexes
Interventional
Phase 1 / Phase 2
Oakland, California, 94609, United States
Although statins have been used extensively for their cholesterol-lowering effects, recent clinical and experimental data indicate that statins regulate yet other processes, many of which play a major role in sickle cell disease (SCD). Independent of their cholesterol-lowering effects, statins have been shown to prevent damage to blood vessels in several ways, through upregulation of endothelial nitric oxide (NO)and decreased inflammation. Numerous studies documenting the protective effects of statins, together with data showing the therapeutic role of NO in SCD, provide the basis for investigating the potential clinical benefit of simvastatin in SCD.
Data supporting the safety and tolerability of simvastatin in patients with SCD are now needed. For this phase I/II dose-escalation study of oral simvastatin in SCD, we propose the following specific aims:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Comparison of 3 dosages of simvastatin given in a dose-escalating fashion. 20 mg, 40 mg, or 80 mg PO QD x 21 days followed by a drug taper x 4 days.
Other names: Zocor
Time frame: Baseline, 21 days
Change in serum total cholesterol level after treatment with simvastatin
Time frame: Baseline, 21 days
Change in plasma hemoglobin (Hb) level after treatment with simvastatin
Time frame: Baseline, 21 days
Change in serum creatine kinase (CK) levels after treatment with simvastatin
Time frame: Baseline, 21 days
Change in serum alanine transaminase (ALT) after treatment with simvastatin
Time frame: Baseline, 21 days
Change in serum creatinine (Cr) levels after treatment with simvastatin
Time frame: Baseline, 21 days
Measurements of the levels of plasma nitric oxide metabolites (NOx), high sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), vascular cell adhesion molecule-1 (VCAM-1), tissue factor (TF) and vascular endothelial growth factor (VEGF)were performed before and after simvastatin treatment. Changes in mean plasma biomarker levels were assessed for each dose level; however, dose level 3 results were not analyzed, as only 2 subjects were enrolled in this dose group.
Time frame: Baseline, 21 days
Change in plasma high sensitivity C-reactive protein levels in subjects treated with simvastatin
Time frame: Baseline, 21 days
Change in plasma IL-6 level after treatment with simvastatin
Time frame: Baseline, 21 days
Change in plasma vascular endothelial adhesion molecule-1 levels after treatment with simvastatin
Time frame: Baseline, 21 days
Change in plasma vascular cellular adhesion molecule-1 levels after treatment with simvastatin
Time frame: Baseline, 21 days
Change in plasma tissue factor (TF) levels after treatment with simvastatin
UCSF Benioff Children's Hospital Oakland
Other
Phase I/II Study of Simvastatin (Zocor) Therapy in Sickle Cell Disease
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05405114
Anemia, Anemia, Hemolytic
Mobile, Alabama, United States
View Trial DetailsNCT07721155
Anemia, Anemia, Hemolytic
Amsterdam, Netherlands
View Trial DetailsNCT03938324
Anemia, Anemia, Hemolytic
Durham, North Carolina, United States
View Trial DetailsNCT00011648
Anemia, Anemia, Hemolytic
Washington D.C., District of Columbia, United States
View Trial Details